Literature DB >> 209723

Possible biochemical basis of memory disorder in Alzheimer disease.

C M Smith, M Swash.   

Abstract

Damage to the hippocampal formation, whether focal or diffuse, leads to severe impairment of short-term memory. The most common presenting symptom of Alzheimer disease is loss of short-term memory, and histologically the hippocampus is characteristically affected. Choline acetyltransferase, which is involved in the synthesis of acetylcholine, is depleted in the hippocampus in the disorder. Anticholinergic drugs administered to normal subjects can simulate some aspects of the memory defect seen in Alzheimer disease. It is postulated that damage to a cholinergic neuronal pathway running to or from the hippocampus underlies the memory disorder. This suggestion implies that it may be possible to improve memory in patients with Alzheimer disease by pharmacological means.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209723     DOI: 10.1002/ana.410030602

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Effects of physostigmine on memory test performance in normal volunteers.

Authors:  C M Smith; J S Coogan; S Hart
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The psychiatrist's role in the care of the elderly.

Authors:  M G Cole; H F Reichenfeld; J R Roy
Journal:  Can Med Assoc J       Date:  1981-04-15       Impact factor: 8.262

Review 3.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

4.  Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.

Authors:  Mark D Lindner; John B Hogan; Donald B Hodges; Anitra F Orie; Ping Chen; Jason A Corsa; John E Leet; Kevin W Gillman; Gregory M Rose; Kelli M Jones; Valentin K Gribkoff
Journal:  Psychopharmacology (Berl)       Date:  2006-09-27       Impact factor: 4.530

Review 5.  Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease.

Authors:  Sofia Jürgensen; Sergio T Ferreira
Journal:  J Mol Neurosci       Date:  2009-08-19       Impact factor: 3.444

6.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

7.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

Review 8.  A rational approach to dementia.

Authors:  A H Ropper
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

9.  The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.

Authors:  Jerry J Buccafusco; Alvin V Terry; Scott J Webster; Daniel Martin; Elizabeth J Hohnadel; Kristy A Bouchard; Samantha E Warner
Journal:  Psychopharmacology (Berl)       Date:  2007-07-27       Impact factor: 4.530

10.  Cognition Enhancing Activity of Sulforaphane Against Scopolamine Induced Cognitive Impairment in Zebra Fish (Danio rerio).

Authors:  Venugopalan Rajesh; Sakthivel Ilanthalir
Journal:  Neurochem Res       Date:  2016-06-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.